Drug Profile
TQ B3456
Alternative Names: TQ-B3456Latest Information Update: 20 Apr 2022
Price :
$50
*
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 20 Apr 2022 TQ B3456 is still in phase-I development in Non-small-cell-lung-cancer(Metastatic disease, Second-line therapy or greater) in China (PO, Tablet) (NCT03754244)
- 29 Mar 2022 Jiangsu Chia-tai Tianqing Pharmaceutical terminates a phase I trial in Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater) in China (PO) (NCT03754244)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Metastatic disease, Second-line therapy or greater) in China (PO, Tablet)